Abstract
Sirolimus, a lipophilic macrolide, is a well-known immunosuppressant drug used for coating coronary stents and for preventing rejection of kidney transplants in humans. Since Sirolimus is a relatively large molecule with an average mass 914.172 g/mol, size exclusion chromatography (SEC) was employed for exploring its potential for the estimation of Sirolimus content from blood samples. When human blood samples were spiked with known concentrations of Sirolimus, it was observed that it could be estimated with an average recovery of >90% and relative standard deviation <5%. Results indicated that Sirolimus could be estimated with impressive accuracy and repeatability by SEC technique.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
